APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Angina Pectoris Medication

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Angina Pectoris Medication Market Outlook and Growth Opportunities 2026

Report ID 173963620427 December 2025199 pages

Choose your research edition.

Industry ResearchAngina Pectoris Medication Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Angina Pectoris Medication Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Angina Pectoris Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angina Pectoris Medication Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Angina Pectoris Medication Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Angina Pectoris Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Angina Pectoris Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angina Pectoris Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angina Pectoris Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Angina Pectoris Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Angina Pectoris Medication market include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Gilead Sciences, Pfizer Inc., GlaxoSmithKline Plc., Otsuka Pharmaceutical Co., Ltd. and Boehringer Ingelheim International GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Angina Pectoris Medication market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angina Pectoris Medication and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angina Pectoris Medication revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Angina Pectoris Medication market.

Angina Pectoris Medication Segment by Company

Sanofi S.A.

Novartis AG

Merck & Co., Inc.

Eli Lilly and Company

Gilead Sciences

Pfizer Inc.

GlaxoSmithKline Plc.

Otsuka Pharmaceutical Co., Ltd.

Boehringer Ingelheim International GmbH

Bayer AG

Amgen Inc.

AstraZeneca

Angina Pectoris Medication Segment by Type

Beta Blockers

Calcium Antagonists

Anticoagulants

Anti-Platelets

Others

Angina Pectoris Medication Segment by Application

Hospitals

Clinics

Others

Angina Pectoris Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Angina Pectoris Medication status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Angina Pectoris Medication key companies, revenue, market share, and recent developments.

3. To split the Angina Pectoris Medication breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Angina Pectoris Medication market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Angina Pectoris Medication significant trends, drivers, influence factors in global and regions.

6. To analyze Angina Pectoris Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angina Pectoris Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angina Pectoris Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angina Pectoris Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Angina Pectoris Medication industry.

Chapter 3: Detailed analysis of Angina Pectoris Medication company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Angina Pectoris Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Angina Pectoris Medication in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Angina Pectoris Medication Industry Trends Table 2. Angina Pectoris Medication Industry Drivers Table 3. Angina Pectoris Medication Industry Opportunities and Challenges Table 4. Angina Pectoris Medication Industry Restraints Table 5. Global Angina Pectoris Medication Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Angina Pectoris Medication Revenue Share by Company (2021-2026) Table 7. Global Angina Pectoris Medication Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Angina Pectoris Medication Key Company Manufacturing Base & Headquarters Table 9. Global Angina Pectoris Medication Company, Product Type & Application Table 10. Global Angina Pectoris Medication Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Angina Pectoris Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Beta Blockers Table 15. Significant Companies of Calcium Antagonists Table 16. Significant Companies of Anticoagulants Table 17. Significant Companies of Anti-Platelets Table 18. Significant Companies of Others Table 19. Global Angina Pectoris Medication Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Angina Pectoris Medication Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Angina Pectoris Medication Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Angina Pectoris Medication Sales Value Share by Type (2021-2026) Table 23. Global Angina Pectoris Medication Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Significant Companies of Others Table 27. Global Angina Pectoris Medication Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Angina Pectoris Medication Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Angina Pectoris Medication Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Angina Pectoris Medication Sales Value Share by Application (2021-2026) Table 31. Global Angina Pectoris Medication Sales Value Share by Application (2027-2032) Table 32. Global Angina Pectoris Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Angina Pectoris Medication Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Angina Pectoris Medication Sales Value Share by Region (2021-2026) Table 35. Global Angina Pectoris Medication Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Angina Pectoris Medication Sales Value Share by Region (2027-2032) Table 37. Global Angina Pectoris Medication Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Angina Pectoris Medication Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Angina Pectoris Medication Sales Value Market Share by Country (2021-2026) Table 40. Global Angina Pectoris Medication Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Angina Pectoris Medication Sales Value Market Share by Country (2027-2032) Table 42. Sanofi S.A. Company Information Table 43. Sanofi S.A. Business Overview Table 44. Sanofi S.A. Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi S.A. Angina Pectoris Medication Product Portfolio Table 46. Sanofi S.A. Recent Development Table 47. Novartis AG Company Information Table 48. Novartis AG Business Overview Table 49. Novartis AG Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Novartis AG Angina Pectoris Medication Product Portfolio Table 51. Novartis AG Recent Development Table 52. Merck & Co., Inc. Company Information Table 53. Merck & Co., Inc. Business Overview Table 54. Merck & Co., Inc. Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Merck & Co., Inc. Angina Pectoris Medication Product Portfolio Table 56. Merck & Co., Inc. Recent Development Table 57. Eli Lilly and Company Company Information Table 58. Eli Lilly and Company Business Overview Table 59. Eli Lilly and Company Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Eli Lilly and Company Angina Pectoris Medication Product Portfolio Table 61. Eli Lilly and Company Recent Development Table 62. Gilead Sciences Company Information Table 63. Gilead Sciences Business Overview Table 64. Gilead Sciences Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Gilead Sciences Angina Pectoris Medication Product Portfolio Table 66. Gilead Sciences Recent Development Table 67. Pfizer Inc. Company Information Table 68. Pfizer Inc. Business Overview Table 69. Pfizer Inc. Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Pfizer Inc. Angina Pectoris Medication Product Portfolio Table 71. Pfizer Inc. Recent Development Table 72. GlaxoSmithKline Plc. Company Information Table 73. GlaxoSmithKline Plc. Business Overview Table 74. GlaxoSmithKline Plc. Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. GlaxoSmithKline Plc. Angina Pectoris Medication Product Portfolio Table 76. GlaxoSmithKline Plc. Recent Development Table 77. Otsuka Pharmaceutical Co., Ltd. Company Information Table 78. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 79. Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Product Portfolio Table 81. Otsuka Pharmaceutical Co., Ltd. Recent Development Table 82. Boehringer Ingelheim International GmbH Company Information Table 83. Boehringer Ingelheim International GmbH Business Overview Table 84. Boehringer Ingelheim International GmbH Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Boehringer Ingelheim International GmbH Angina Pectoris Medication Product Portfolio Table 86. Boehringer Ingelheim International GmbH Recent Development Table 87. Bayer AG Company Information Table 88. Bayer AG Business Overview Table 89. Bayer AG Angina Pectoris Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Bayer AG Angina Pectoris Medication Product Portfolio Table 91. Bayer AG Recent Development Table 92. Amgen Inc. Company Information Table 93. Amgen Inc. Business Overview Table 94. Amgen Inc. Angina Pectoris Medication Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Amgen Inc. Angina Pectoris Medication Product Portfolio Table 96. Amgen Inc. Recent Development Table 97. AstraZeneca Company Information Table 98. AstraZeneca Business Overview Table 99. AstraZeneca Angina Pectoris Medication Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AstraZeneca Angina Pectoris Medication Product Portfolio Table 101. AstraZeneca Recent Development Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Angina Pectoris Medication Product Image Figure 2. Global Angina Pectoris Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angina Pectoris Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global Angina Pectoris Medication Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Beta Blockers Image Figure 8. Calcium Antagonists Image Figure 9. Anticoagulants Image Figure 10. Anti-Platelets Image Figure 11. Others Image Figure 12. Global Angina Pectoris Medication Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Angina Pectoris Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Angina Pectoris Medication Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Others Image Figure 18. Global Angina Pectoris Medication Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Angina Pectoris Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Angina Pectoris Medication Sales Value Share by Application (2021-2032) Figure 21. Global Angina Pectoris Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Angina Pectoris Medication Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Angina Pectoris Medication Sales Value (2021-2032) & (US$ Million) Figure 24. North America Angina Pectoris Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Angina Pectoris Medication Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Angina Pectoris Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Angina Pectoris Medication Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Angina Pectoris Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Angina Pectoris Medication Sales Value (2021-2032) & (US$ Million) Figure 30. South America Angina Pectoris Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Angina Pectoris Medication Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Angina Pectoris Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Angina Pectoris Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Blockers
  • Calcium Antagonists
  • Anticoagulants
  • Anti-Platelets
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Sanofi S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Amgen Inc.
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Angina Pectoris Medication Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Angina Pectoris Medication Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Angina Pectoris Medication Market Dynamics
  1. 2.1 Angina Pectoris Medication Industry Trends
  2. 2.2 Angina Pectoris Medication Industry Drivers
  3. 2.3 Angina Pectoris Medication Industry Opportunities and Challenges
  4. 2.4 Angina Pectoris Medication Industry Restraints
3 Angina Pectoris Medication Market by Company
  1. 3.1 Global Angina Pectoris Medication Company Revenue Ranking in 2025
  2. 3.2 Global Angina Pectoris Medication Revenue by Company (2021-2026)
  3. 3.3 Global Angina Pectoris Medication Company Ranking (2024-2026)
  4. 3.4 Global Angina Pectoris Medication Company Manufacturing Base and Headquarters
  5. 3.5 Global Angina Pectoris Medication Company Product Type and Application
  6. 3.6 Global Angina Pectoris Medication Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Angina Pectoris Medication Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Angina Pectoris Medication Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Angina Pectoris Medication Market by Type
  1. 4.1 Angina Pectoris Medication Type Introduction
  2. 4.1.1 Beta Blockers
  3. 4.1.2 Calcium Antagonists
  4. 4.1.3 Anticoagulants
  5. 4.1.4 Anti-Platelets
  6. 4.1.5 Others
  7. 4.2 Global Angina Pectoris Medication Sales Value by Type
  8. 4.2.1 Global Angina Pectoris Medication Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Angina Pectoris Medication Sales Value by Type (2021-2032)
  10. 4.2.3 Global Angina Pectoris Medication Sales Value Share by Type (2021-2032)
5 Angina Pectoris Medication Market by Application
  1. 5.1 Angina Pectoris Medication Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Angina Pectoris Medication Sales Value by Application
  6. 5.2.1 Global Angina Pectoris Medication Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Angina Pectoris Medication Sales Value by Application (2021-2032)
  8. 5.2.3 Global Angina Pectoris Medication Sales Value Share by Application (2021-2032)
6 Angina Pectoris Medication Regional Value Analysis
  1. 6.1 Global Angina Pectoris Medication Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angina Pectoris Medication Sales Value by Region (2021-2032)
  3. 6.2.1 Global Angina Pectoris Medication Sales Value by Region: 2021-2026
  4. 6.2.2 Global Angina Pectoris Medication Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Angina Pectoris Medication Sales Value (2021-2032)
  7. 6.3.2 North America Angina Pectoris Medication Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Angina Pectoris Medication Sales Value (2021-2032)
  10. 6.4.2 Europe Angina Pectoris Medication Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Angina Pectoris Medication Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Angina Pectoris Medication Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Angina Pectoris Medication Sales Value (2021-2032)
  16. 6.6.2 South America Angina Pectoris Medication Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Angina Pectoris Medication Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Angina Pectoris Medication Sales Value Share by Country, 2025 VS 2032
7 Angina Pectoris Medication Country-level Value Analysis
  1. 7.1 Global Angina Pectoris Medication Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Angina Pectoris Medication Sales Value by Country (2021-2032)
  3. 7.2.1 Global Angina Pectoris Medication Sales Value by Country (2021-2026)
  4. 7.2.2 Global Angina Pectoris Medication Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Angina Pectoris Medication Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Angina Pectoris Medication Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Angina Pectoris Medication Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi S.A.
  2. 8.1.1 Sanofi S.A. Company Information
  3. 8.1.2 Sanofi S.A. Business Overview
  4. 8.1.3 Sanofi S.A. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi S.A. Angina Pectoris Medication Product Portfolio
  6. 8.1.5 Sanofi S.A. Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Angina Pectoris Medication Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. Angina Pectoris Medication Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Eli Lilly and Company
  20. 8.4.1 Eli Lilly and Company Company Information
  21. 8.4.2 Eli Lilly and Company Business Overview
  22. 8.4.3 Eli Lilly and Company Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly and Company Angina Pectoris Medication Product Portfolio
  24. 8.4.5 Eli Lilly and Company Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Angina Pectoris Medication Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 Pfizer Inc.
  32. 8.6.1 Pfizer Inc. Company Information
  33. 8.6.2 Pfizer Inc. Business Overview
  34. 8.6.3 Pfizer Inc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Inc. Angina Pectoris Medication Product Portfolio
  36. 8.6.5 Pfizer Inc. Recent Developments
  37. 8.7 GlaxoSmithKline Plc.
  38. 8.7.1 GlaxoSmithKline Plc. Company Information
  39. 8.7.2 GlaxoSmithKline Plc. Business Overview
  40. 8.7.3 GlaxoSmithKline Plc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Plc. Angina Pectoris Medication Product Portfolio
  42. 8.7.5 GlaxoSmithKline Plc. Recent Developments
  43. 8.8 Otsuka Pharmaceutical Co., Ltd.
  44. 8.8.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Product Portfolio
  48. 8.8.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Boehringer Ingelheim International GmbH
  50. 8.9.1 Boehringer Ingelheim International GmbH Company Information
  51. 8.9.2 Boehringer Ingelheim International GmbH Business Overview
  52. 8.9.3 Boehringer Ingelheim International GmbH Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim International GmbH Angina Pectoris Medication Product Portfolio
  54. 8.9.5 Boehringer Ingelheim International GmbH Recent Developments
  55. 8.10 Bayer AG
  56. 8.10.1 Bayer AG Company Information
  57. 8.10.2 Bayer AG Business Overview
  58. 8.10.3 Bayer AG Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer AG Angina Pectoris Medication Product Portfolio
  60. 8.10.5 Bayer AG Recent Developments
  61. 8.11 Amgen Inc.
  62. 8.11.1 Amgen Inc. Company Information
  63. 8.11.2 Amgen Inc. Business Overview
  64. 8.11.3 Amgen Inc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Inc. Angina Pectoris Medication Product Portfolio
  66. 8.11.5 Amgen Inc. Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Angina Pectoris Medication Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst